Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.34 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.34 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.34 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.34 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2408016 | 0.74 | TRPV6 (0.41) | PCSK9ORAI1ORAI2ORAI3TRPV6 | |
| SCHEMBL341836 | 0.70 | TAAR1 (0.47) | PCSK9ORAI1ORAI2ORAI3TRPV6 | |
| SCHEMBL2400587 | 0.69 | ORAI1 (0.42) | PCSK9ORAI1ORAI2ORAI3TRPV6 | |
| SCHEMBL2400530 | 0.68 | TRPV6 (0.48) | PCSK9ORAI1ORAI2ORAI3TRPV6 | |
| Methyl Alcohol SCHEMBL27541809 | 0.67 | TAAR1 (0.44) | PCSK9ORAI1ORAI2ORAI3TRPV6 | |
| SCHEMBL1469675 | 0.66 | TRPV6 (0.50) | PCSK9ORAI1ORAI2ORAI3TRPV6 | |
| SCHEMBL3274578 | 0.66 | TRPV6 (0.50) | PCSK9ORAI1ORAI2ORAI3TRPV6 | |
| SCHEMBL12271157 | 0.66 | TRPV6 (0.50) | PCSK9ORAI1ORAI2ORAI3TRPV6 | |
| SCHEMBL2405995 | 0.65 | ORAI1 (0.38) | PCSK9ORAI1ORAI2ORAI3TRPV6 | |
| SCHEMBL2405808 | 0.64 | TRPV6 (0.72) | PCSK9ORAI1ORAI2ORAI3TRPV6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1961756-B1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE & TECH AGENCY (JP) | 2016-04-27 | — | — | EP | claimed |
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | BAZ2B, PRMT1, BRIX1 | PCSK9 2110/4885ORAI1 4605/4885ORAI2 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.